Ganaxolone
Small molecule
Evidence outlook
Approved: Epilepsy, Developmental and Epileptic Encephalopathies
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01963208 NCT01963208 · Drug Resistant Partial Onset Seizure The primary phase was well controlled, with randomized quadruple blinding, placebo comparison, and 350 analyzed participants, and it used the clinical endpoint of change in seizure frequency. However, the primary endpoint was missed: the difference between ganaxolone and placebo was not statistically significant (p=0.1788), so the study provides well-designed but inconclusive evidence. Registry: NCT01963208 | 3 | Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14) 2016-05 | Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) | Partial signal | link ↗ |
View 1 more trial
RAISE NCT04391569 · Status Epilepticus The trial randomized 100 participants to ganaxolone or placebo and used blinded treatment, with 49 and 47 participants contributing to the primary efficacy analyses. Although the 30-minute seizure-cessation endpoint favored ganaxolone significantly, the 36-hour avoidance-of-anesthesia endpoint was not statistically significant, so the primary results were discordant. Registry: NCT04391569 | 3 | Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes); Percentage of Participants With no Progression to Intravenous (IV) Anesthesia for 36 Hours Following Investigational Product (IP) Initiation (Up to 36 hours after IP initiation); Number of Participants With Treatment Emergent Adverse Events (Up to 4 weeks after IP initiation) 2024-03-30 | Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other GABA-A receptor drugs
Clobazam (Onfi), Diazepam (Diastat), Diazepam (Valium), Diazepam (Valtoco), Lorazepam and 9 more. Compare all 15 GABA-A receptor drugs
This mechanism is crowded: 14 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ganaxolone: this drug | Approved | Small molecule | GABA-A receptor | Partial signal | NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Reliable signal | NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001). NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Vigabatrin (Vigafyde) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| KH607 | Phase 3(overall) | Small molecule | GABA-A receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| GlyphAllo (allopregnanolone Prodrug) (SPT-300) | Phase 2(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HS-10353 | Phase 2(overall) | Small molecule | GABA-A receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Remimazolam | Phase 1(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ganaxolone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.